Ruxience Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Ruxience Indications
Indications
Ruxience Dosage and Administration
Adult
Children
Other Modifications
Females and Males of Reproductive Potential
-
Pregnancy Testing: Verify pregnancy status in females of reproductive potential prior to initiating Ruxience.
-
Contraception (Females): Advise females of reproductive potential to use effective contraception during treatment with Ruxience and for 12 months after the last dose.
Ruxience Contraindications
Not Applicable
Ruxience Boxed Warnings
Boxed Warning
Ruxience Warnings/Precautions
Warnings/Precautions
Ruxience Pharmacokinetics
Distribution
Volume of distribution: 3.1 L (RA) and 3.12 L (GPA/MPA).
Elimination
Terminal half-life: 18 days (RA; range, 5.17 to 77.5 days); 22 days (NHL; range, 6.1 to 52 days); 25 days (GPA/MPA; range, 11 to 52 days); 32 days (CLL; range, 14 to 62 days).
Ruxience Interactions
Interactions
Ruxience Adverse Reactions
Adverse Reactions
Ruxience Clinical Trials
Ruxience Note
Not Applicable
Ruxience Patient Counseling
Cost Savings Program
The Ruxience savings program is available here.
Ruxience Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Ruxience Indications
Indications
Ruxience Dosage and Administration
Adult
Children
Other Modifications
Females and Males of Reproductive Potential
-
Pregnancy Testing: Verify pregnancy status in females of reproductive potential prior to initiating Ruxience.
-
Contraception (Females): Advise females of reproductive potential to use effective contraception during treatment with Ruxience and for 12 months after the last dose.
Ruxience Contraindications
Not Applicable
Ruxience Boxed Warnings
Boxed Warning
Ruxience Warnings/Precautions
Warnings/Precautions
Ruxience Pharmacokinetics
Distribution
Volume of distribution: 3.1 L (RA) and 3.12 L (GPA/MPA).
Elimination
Terminal half-life: 18 days (RA; range, 5.17 to 77.5 days); 22 days (NHL; range, 6.1 to 52 days); 25 days (GPA/MPA; range, 11 to 52 days); 32 days (CLL; range, 14 to 62 days).
Ruxience Interactions
Interactions
Ruxience Adverse Reactions
Adverse Reactions
Ruxience Clinical Trials
Ruxience Note
Notes
Ruxience Patient Counseling
Cost Savings Program
The Ruxience savings program is available here.
Ruxience Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Ruxience Indications
Indications
Ruxience Dosage and Administration
Adult
Children
Other Modifications
Females and Males of Reproductive Potential
-
Pregnancy Testing: Verify pregnancy status in females of reproductive potential prior to initiating Ruxience.
-
Contraception (Females): Advise females of reproductive potential to use effective contraception during treatment with Ruxience and for 12 months after the last dose.
Ruxience Contraindications
Not Applicable
Ruxience Boxed Warnings
Boxed Warning
Ruxience Warnings/Precautions
Warnings/Precautions
Ruxience Pharmacokinetics
Distribution
Volume of distribution: 3.1 L (RA) and 3.12 L (GPA/MPA).
Elimination
Terminal half-life: 18 days (RA; range, 5.17 to 77.5 days); 22 days (NHL; range, 6.1 to 52 days); 25 days (GPA/MPA; range, 11 to 52 days); 32 days (CLL; range, 14 to 62 days).
Ruxience Interactions
Interactions
Ruxience Adverse Reactions
Adverse Reactions
Ruxience Clinical Trials
Ruxience Note
Not Applicable
Ruxience Patient Counseling
Cost Savings Program
The Ruxience savings program is available here.